Immune checkpoint inhibitors in high‐grade upper tract urothelial carcinoma: Paradigm shift emphasizing organ preservation
Khalil M, Fishman A, Komorowski A, Franco I, Grasso M. Immune checkpoint inhibitors in high‐grade upper tract urothelial carcinoma: Paradigm shift emphasizing organ preservation. BJUI Compass 2024, 5: 490-496. PMID: 38751949, PMCID: PMC11090768, DOI: 10.1002/bco2.335.Peer-Reviewed Original ResearchImmune check point inhibitorsHigh-grade upper tract urothelial carcinomaUpper tract urothelial carcinomaMetastasis-free survival ratesGroup 2Group 1Survival rateUrothelial carcinomaSurvival outcomesMedian follow-up periodImpact of clinical characteristicsCheck-point inhibitorsImmune checkpoint inhibitorsEndoscopically treated patientsInitial tumor sizeImprove survival outcomesOverall survival rateKaplan-Meier analysisFollow-up periodImproved survival ratesCheckpoint inhibitorsPoint inhibitorsExtirpative surgeryTumor sizeClinical characteristics